Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep;80(9):1036-9.
doi: 10.1136/jnnp.2008.155325.

Rituximab for polyneuropathy with IgM monoclonal gammopathy

J M F Niermeijer  1 , M Eurelings, H L Lokhorst, W-L van der Pol, H Franssen, J H J Wokke, N C Notermans
Affiliations
Clinical Trial

Rituximab for polyneuropathy with IgM monoclonal gammopathy

J M F Niermeijer et al. J Neurol Neurosurg Psychiatry. 2009 Sep.

Abstract

Background: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment.

Methods: In a prospective open label trial, 17 patients with disabling IgM MGUS polyneuropathy were treated with rituximab, a chimeric anti-CD-20 monoclonal antibody.

Results: Rituximab induced an improvement of >or=1 point on the Overall Disability Sum Score in 2/17 patients, an improvement of >or=5% of the distal MRC sum score in 4/17 and the sensory sum score in 9/17 patients. Bone marrow investigations showed CD 20 B cell depletion in all patients. There were no serious adverse events. Compared with treatment with intermittent cyclophosphamide with prednisone or treatment with fludarabine, it shows a comparable response percentages but fewer side effects. The presence of anti-MAG and a disease duration shorter than 10 years may predict treatment response.

Conclusion: Rituximab is a candidate for treatment of IgM MGUS polyneuropathy and should be further investigated in a double-blind randomised trial.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources